(a) |
| | Study | Location | Baseline data comparable | Disease duration (average) | Average age (years) | Course of treatment (weeks) | Sample Size | FUP (months) | Adverse events | | E | C | E | C | E | C | E | C |
| | Qu Y, 2014 | China | Yes | 10.7 (6.1) y | 10.7 (6.1) y | 54.6 (16.5) | 54.6 (16.5) | 8 | 35 | 34 | NR | Pain (2) | 0 |
| | Yang SQ, 2014 | China | Yes | NR | NR | NR | NR | 4 | 61 | 60 | NR | NR | NR |
| | Li B, 2015 | China | Yes | 2 y | 2 y | 40 | 40 | 4 | 40 | 40 | NR | Erythema and swelling (5) | 0 |
| | Zhang JB, 2015 | China | Yes | 5.63 (3.22) y | 5.78(3.12) y | 23.42(4.51) | 22.9(5.12) | 4 | 49 | 46 | 6 | Pain (5) | Blister (27) |
| | Wang JZ, 2015 | China | Yes | 6.78 (3.6) y | 6(3.29) y | 32.91(6.91) | 31.09(5,21) | 4 | 37 | 38 | NR | NR | NR |
| | Pan HY, 2015 | China | Yes | 6 (2.85) m | 5.91 (2.64) m | 34.94(5.79) | 35.06(6.19) | 8 | 34 | 34 | NR | Dizziness (1) | Irregular menstruation (1), stomach ache (1) |
| | Zhao JL, 2016 | China | Yes | 18 m | 18 m | 41 | 41 | 4 | 28 | 24 | NR | Thirst (2), drowsiness (2), erythema and swelling (1) | Thirst (2), drowsiness (3) |
| | Chen XM, 2016 | China | Yes | 3.62 (1.55) y | 3.51 (1.95) y | 31.22 (5.64) | 31.42 (5.27) | 4 | 32 | 31 | 3m | Pain (2), pruritus with skin bruises (1) | Dizziness (1) |
| | Li GF, 2017 | China | Yes | 5.1 (2.2) y | 5.2 (2) y | 40.3 (2.3) | 42.1 (2.0) | 4 | 40 | 40 | 6m | NR | NR |
| | Wang J, 2017 | China | Yes | 2–8 y | 2–8 y | 38 | 38 | 4 | 50 | 50 | NR | NR | NR |
| | Liu M, 2017 | China | Yes | 9.23 (2.19) m | 9.56 (2.36) m | 39.88 (3.36) | 38.98 (3.69) | 4 | 25 | 25 | NR | NR | NR |
| | Mei CF, 2017 | China | Yes | 20.67 (10.28) m | 18.63 (9.43) m | 42.1 (19.48) | 43.3 (14.38) | 8 | 30 | 30 | NR | Dizziness (2) | Thirst (2), drowsiness (3) |
| | Deng QF, 2018 | China | Yes | 4.57 (1.6) y | 4.23 (1.56) y | 38.41 (4.62) | 37.56 (4.56) | 4 | 34 | 34 | NR | NR | NR |
| | Hu FM, 2018 | China | Yes | 2 (2.3) y | 2 (2.5) y | 35 (8.8) | 38 (8.2) | 4 | 60 | 60 | NR | Erythema and swelling (2) | 0 |
|
|
E: experimental group (fire needle therapy alone or combined with conventional therapy), C: control group (only the conventional therapy used in the experimental group), NR: no report, FUP: follow-up period, T: true, RCT: randomized controlled trial, w: weeks, m: months, y: years, SSRI: Symptom Score Reducing Index, VAS: visual analog scale, DLQI: Dermatology Life Quality Index, RER: recurrence rate, and AEs: adverse events.
|
(b) |
| | Study | RCT | Recurrence | Interventions | Main outcomes | | E | C | E | C |
| | Qu Y, 2014 | T | NR | NR | Fire needle/fire needle + Longmu decoction | Longmu decoction | Total effectiveness rate, SSRI, AEs |
| | Yang SQ, 2014 | T | NR | NR | Fire needle + Quanchong prescription | Quanchong prescription | Total effectiveness rate |
| | Li B, 2015 | T | NR | NR | Fire needle/fire needle + Halometasone cream | Halometasone cream | Total effectiveness rate |
| | Zhang JB, 2015 | T | 2 | 3 | Fire needle | Liquid nitrogen refrigeration | Total effectiveness rate, AEs |
| | Wang JZ, 2015 | T | NR | NR | Fire needle + modified Wendan Decoction | modified Wendan decoction | Total effectiveness rate |
| | Pan HY, 2015 | T | NR | NR | Fire needle + Quanchong decoction | Quanchong decoction | Total effectiveness rate SSRI, VAS, DLQI, AEs |
| | Zhao JL, 2016 | T | NR | NR | Fire needle + Thalidomide +mometasone furoate | Thalidomide + mometasone furoate | Total effectiveness rate |
| | Chen XM, 2016 | T | 4 | 9 | Fire needle | Halometasone cream | Total effectiveness rate, SSRI, VAS, DLQI, RER, AEs |
| | Li GF, 2017 | T | 2 | 4 | Fire needle + Halometasone cream | Halometasone cream | Total effectiveness rate, RER |
| | Wang J, 2017 | T | NR | NR | Fire needle + Triamcinolone acetonide injection | Triamcinolone acetonide injection | Total effective rate |
| | Liu M, 2017 | T | NR | NR | Fire needle | Compound Wendan decoction | Total effectiveness rate |
| | Mei CF, 2017 | T | NR | NR | Fire needle + Thalidomide | Thalidomide | Total effectiveness rate, AEs |
| | Deng QF, 2018 | T | NR | NR | Fire needle | Halometasone cream | Total effectiveness rate, SSRI, VAS |
| | Hu FM, 2018 | T | NR | NR | Fire needle + Quanchong decoction | Quanchong decoction | Total effectiveness rate, SSRI, AEs |
|
|
E: experimental group (fire needle therapy alone or combined with conventional therapy), C: control group (only the conventional therapy used in the experimental group), NR: no report, FUP: follow-up period, T: true, RCT: randomized controlled trial, w: weeks, m: months, y: years, SSRI: Symptom Score Reducing Index, VAS: visual analog scale, DLQI: Dermatology Life Quality Index, RER: recurrence rate, and AEs: adverse events.
|
